- Home
- CALX vs NVCR Comparison
CALX vs NVCR Comparison
Compare CALX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALX
- NVCR
- Stock Information
- Founded
- CALX 1999
- NVCR 2000
- Country
- CALX United States
- NVCR Jersey
- Employees
- CALX N/A
- NVCR N/A
- Industry
- CALX Telecommunications Equipment
- NVCR Medical/Dental Instruments
- Sector
- CALX Consumer Discretionary
- NVCR Health Care
- Exchange
- CALX Nasdaq
- NVCR Nasdaq
- Market Cap
- CALX 2.4B
- NVCR 1.8B
- IPO Year
- CALX 2010
- NVCR 2015
- Fundamental
- Price
- CALX $37.11
- NVCR $17.49
- Analyst Decision
- CALX Strong Buy
- NVCR Buy
- Analyst Count
- CALX 6
- NVCR 5
- Target Price
- CALX $42.50
- NVCR $26.60
- AVG Volume (30 Days)
- CALX 368.7K
- NVCR 1.3M
- Earning Date
- CALX 10-28-2024
- NVCR 10-30-2024
- Dividend Yield
- CALX N/A
- NVCR N/A
- EPS Growth
- CALX N/A
- NVCR N/A
- EPS
- CALX N/A
- NVCR N/A
- Revenue
- CALX $890,128,000.00
- NVCR $549,964,000.00
- Revenue This Year
- CALX N/A
- NVCR $16.23
- Revenue Next Year
- CALX $4.01
- NVCR $6.09
- P/E Ratio
- CALX N/A
- NVCR N/A
- Revenue Growth
- CALX N/A
- NVCR 8.33
- 52 Week Low
- CALX $26.76
- NVCR $10.87
- 52 Week High
- CALX $45.15
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- CALX 50.00
- NVCR 43.24
- Support Level
- CALX $36.89
- NVCR $15.61
- Resistance Level
- CALX $40.41
- NVCR $17.31
- Average True Range (ATR)
- CALX 1.16
- NVCR 1.29
- MACD
- CALX -0.08
- NVCR 0.05
- Stochastic Oscillator
- CALX 34.89
- NVCR 11.59
About CALX Calix Inc
Calix Inc develops, market and sell Calix cloud, systems and software platforms to enable service providers of all types and sizes to innovate and transform. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.